MarketLens

What is Pfizer's Braftovi and Why Does it Matter for Investors

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What is DecisionDx-Melanoma and Why Does it Matter for Investors

4 months ago

What Does a Senator's Bond Purchase Mean for Pfizer Investors

4 months ago

What is Agentic Testing and Why Does it Matter for Enterprises

2 months ago

What is PanTracer Pro and Why Does it Matter for Cancer Diagnostics

6 months ago

Pfizer's Obesity Push: Can Berobenatide Take Market Share?

Pfizer is advancing berobenatide, a potential monthly obesity treatment, to compete with leading GLP-1 therapies. The move targets a high-growth market, though no clinical or regulatory milestones wer...

PFE

Stock News•1 months ago

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

The race for the next standard cancer treatment is focusing on pairing two innovations, as the market looks beyond Merck's Keytruda.

MRK

Stock News•1 months ago

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BridgeBio Oncology Therapeutics fell >30% since prior coverage, but remains a Buy with BB-8520 showing 65% ORR and 100% DCR in KRAS G12C NSCLC. Mature data readouts due 2H26 could be key catalysts.

BBOT

Stock News•2 months ago

How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers

Pfizer’s Braftovi-based regimen nearly doubled progression-free survival for colon cancer patients in a recent study. This clinical success could strengthen the company's oncology portfolio and improv...

PFE